A court in the United States has allowed four e-cigarette companies whose applications were rejected by the FDA to resume sales
On February 1, the 11th Circuit Court of Appeals granted four nicotine vaporator manufacturers (Bidi Vapor, Diamond Vapor, Johnny Cooper, and Vapor Unlimited) an injunction against their MDO issued by the U.S. Food and Drug Administration (FDA). The decision means those manufacturers can continue to sell their harm reduction products as long as the lawsuit remains in force.
[These companies] followed dozens of other e-cigarette companies in taking legal action against the FDA after the agency rejected thousands of products through its new Premarket Tobacco Product Application (PMTA) pathway.
What happens in the process?
During the PMTA process, the FDA must determine whether the introduction is "appropriate to protect public health," a confusing standard now understood as the likelihood that a given product will help adult smokers transition to smoking. Safer alternatives without introducing a new generation to nicotine.
The FDA has until September 2021 to review all applications filed by e-cigarette companies a year ago, but has had trouble with paperwork. So far, the agency has authorized only one e-cigarette product and two tobacco-flavored bombs, rejected thousands of PMTas from small and medium-sized businesses, and deferred decisions on the companies with the largest market share.
Many manufacturers who received Mdos and filed lawsuits with the FDA made nearly the same argument, insisting that the agency acted "arbitrarily" and "capricious" in denying their PMTA.
More specifically, they revealed how the FDA changed its PMTA standards after the submission deadline and never opened any useful channels of communication, leaving manufacturers suspicious and then struggling to meet ever-changing goals. As Filter reports, the agency appears to use an extensive "fatal flaw" list approach to determine whether applications include two specific types of long-term studies, and if not, without looking at any other data or information, including marketing plans.
BIDI case
"Obviously, (...) FDA led Bidi to conclude that it did not necessarily require a long-term study."
Take Bidi: It took the company two years to assemble its PMTA at a cost of about $6.6 million, according to court documents.
Manufacturers submitted 285,000 pages of information, "including data on health and toxicological hazards, marketing limitations and reviews of the scientific literature," and "demonstrated that the products provide substantial benefits in reducing relative health risks [compared to smoking]."
But the FDA apparently did not review any of these, leading Bidi to conclude that it did not necessarily need long-term studies. (The FDA previously issued an administrative stay to Bidi in October, so the manufacturer has technically been allowed to sell its products since then without fear of enforcement.)
Notably, in response to Bidi's request for a pre-PMTA meeting in February 2020 to discuss product comparative testing requirements, FDA sent a letter specifying that it did not require "the applicant to conduct clinical trials or trials in support of PMTA," according to a Bidi Court report, "No specific requirements for evaluating comparative products".
"In fact, FDA has never said that Bidi should compare the smoking cessation benefits of its unflavored tobacco products to flavored tobacco products, and [that] the lack of such research, without any scientific review, will automatically lead to MDO."
Where will the avalanche of lawsuits go?
In addition to the 11th Circuit, appeals courts are also dealing with similar lawsuits: In October, the Fifth Circuit granted a stay of Triton Distribution, as well as a scathing opinion criticizing the FDA. (The judges recently heard oral arguments on whether Triton's MDO should be canceled, and they wavered a bit on the issue.) Meanwhile, the Sixth Circuit denied Breeze Smoke's motion for a similar stay.
It's too early to say, but different decisions by different circuits in very similar cases could end up in the Supreme Court.

